India: Abraxene’s Consecutive Rebuttal By Indian Patent Office

Last Updated: 13 October 2014
Article by Saipriya Balasubramanian

Most Read Contributor in India, September 2016

Indian Patent office, for the consecutive time rejects the grant of patent for an anti-cancer drug named 'Abraxene' developed by Abraxis Bioscience Inc which is a US-based biotechnology firm. IPO rejected the patent application for the second time, following an order passed by the Intellectual Property Appellate Board (IPAB) on the 20th of January, 2014 for fresh consideration of claims.


Abraxene is an injectible formulation of protein bound particles (paclitaxel) primarily used in the treatment of breast cancer, lung cancer and pancreatic cancer. On 29th June 2009 a patent Application titled 'Composition and method for delivery of pharmacological agents' bearing application No: 2899/DELNP/2005 was filed in India by Abraxis Biosciences claiming priority from a US patent application filed on the 9th of December, 20021 . NATCO filed a pre-grant opposition on several grounds including lack of novelty, after the said application was published in the official gazette. On 24th July 2009, IPO rejected the patent based on u/s 2(1)(j), u/s 3(e ) and u/s 10 of the Patents Act, 1970. Aggrieved by the decision of IPO, the Applicant Abraxis filed an appeal numbered M.P.NO. 57/2010 IN OA/3/2010/PT/DEL and OA/3/2010/PT/DEL in 'Intellectual Property Appellate Board' (IPAB) against said decision of the Controller.


Abraxis argued in their appeal that the order passed by the Controller reflected the violation of principle of natural justice as they were denied an opportunity of being heard. Giving an opportunity to the Applicant to be heard and clarify the objections raised by the IPO is a mandatory requirement as per Section 14 and 15 of the Indian Patents Act 1970. It was further mentioned in the order passed by the Controller that the Applicant has not filed any reply to FER within the prescribed time period which was vehemently denied by the Applicant who reiterated that they had filed the reply to FER within the prescribed time.

Abraxis strongly pointed out that the Assistant Controller of Patents and Designs took the decision based on the ground of insufficiency which was not at all raised by NATCO.


In the order (Order No. 9 of 2014) dated 20th January 2014, the IPAB in its decision set aside the said Controller's order and remanded the matter to the Assistant Controller for a fresh consideration by affording opportunity to both sides based on the Principle of Natural Justice.


As per the directions of Hon'ble IPAB, hearing was held on 01/04/2014 and 02/04/2014.Further NATCO filed a fresh representation u/s 25(1) on 28/03/2014 under the grounds of section 25(1)(g) and 25(1)(f ) limited to section 3(d). The said representation was forwarded to the applicant. The applicant filed reply statement on 15/04/2014. The hearing on the fresh representation was held on 17/04/2014.


The Controller explained in detail regarding the admissibility of fresh representation by the opponent. It was contended that the second representation is considered as a fresh representation and not a 'serial opposition' as the opponent was unaware of the amended claims 1-12 which claims 1-93 was previously. Owing to the fact that the scope of amended claims is different from that of the original claims, the Controller upheld this contention and the fresh representation were taken on record.


Ground u/s 25(1)(b)- The claims lack novelty: In respect of the contention on the ground of lack of novelty raised by the opponent it was held by the controller that the prior art document does not disclose each and every element of the instant claimed composition, therefore the invention does not lack any novelty thereby dismissing the contentions u/s 25(1)(b). Ground u/s 25(1)(d)- The claims are in public use/ publicly known: The Controller held that the referred prior art document WO'079 does not disclose the composition as claimed fully, therefore through the said reference the instant claimed composition was not available to the public before the priority date of the instant application. Therefore the contention that the claims are in public use or publicly known under section 25 (1)(d) was also dismissed.


Ground u/s 25(1)(e)- The claims lack inventive step: The contention raised by the opponent u/s 25 (1)(e) that the claims lack inventive steps was upheld by the Controller as the applicant failed to provide any substantial evidence regarding the improved unexpected properties in the claimed composition as contended by the applicant. Moreover, the teaching of cited reference reveals that a person having ordinary skill in the art would have sufficient teaching/ suggestion and motivation to reach at every element of the claimed composition.


The opponent raised contention u/s 25 (1)(f ) that the claims are not patentable u/s 3(e) and 3(d).Hearing the arguments of both parties, the Controller held that the applicant did not provide any comparative data in support of the unforeseen effect. Also, the examples given in the specification are more of routine pharmacological study of the composition to analyze therapeutic and toxicological effect on the body on the administration of claimed composition.

The applicant had mentioned in the complete specification that by his invention the associated sideeffects of said composition are reduced and enhancing transportation of claimed composition. However, the specification neither indicated any enhance effect of paclitaxel nor demonstrated any significance of such properties with regard to 'therapeutic efficacy' in view of the known substance. Therefore, in absence of any therapeutic efficacy of the composition as claimed, the amended claims 1 to 12 fall u/s 3(d) of the Patents Act, 1970 and make the invention non-patentable.

The contentions raised under section 3(e) , it was held by the Controller that the claimed composition is considered as a mere admixture resulting only in the aggregation of the properties and therefore, the instant amended claims 1 to 12 falls under section 3(e) of the Patents Act, 1970.Further, in light of the teachings of prior art references, the invention is a product of routine experimentation work of a skilled artisan, therefore the invention falls under the purview of section 3(e) of the Indian Patents Act, 1970 and is non-patentable.


The Controller held that the specification failed to provide a specific working example of the best mode of performing invention and hence amounted to insufficiency of disclosure as provided by applicant.


The decision of patent denial to Abraxene would benefit the domestic pharmaceutical companies to launch affordable versions of the drug in the local market. On the other hand, Abraxis can either appeal the order in front of IPAB again, or file a Writ petition. If the order of the IPO is upheld, it is a win for generic drug manufacturers such as Natco and Cipla Natco's version, Albupax, was the first indigenously developed nanotech-based cancer drug. But it landed into problems after a year of launch, being charged with safety concerns by the drug controller. After clearing the hurdles, Natco is yet to launch the drug. Other companies like Cipla launched the drug Paclitax Nab (nano particle albumin bound) for the treatment of metastatic breast cancertion in 2012, at around Rs 11,000 per injection2.




The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.